EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease

被引:21
作者
Angelopoulou, MK [1 ]
Vassilakopoulos, TP [1 ]
Siakantaris, MP [1 ]
Kontopidou, FN [1 ]
Boussiotis, VA [1 ]
Papavassiliou, C [1 ]
Kittas, C [1 ]
Pangalis, GA [1 ]
机构
[1] Univ Athens, Laikon Gen Hosp, Sch Med, Dept Internal Med 1,Hematol Sect, Athens 11527, Greece
关键词
Hodgkin's disease; early stage; combined modality;
D O I
10.3109/10428190009057636
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the efficacy of EBVD combination chemotherapy followed by low dose (LD) involved field (LF) radiation therapy (RT) in patients with clinical stage (CS) I-IIA Hodgkin's disease (HD), we analyzed 148 patients treated in our Unit from March 1988 to November 1995, EBVD consisted of Epirubicine 40mg/m(2), Bleomycin 10mg/m(2), Vinblastine 6mg/m(2) and Dacarbazine 300mg. All drugs were administered i.v, at days 1 and 15, every 4 weeks, for a total of 4-6 cycles. LDIF RT (24-32Gy) was scheduled for patients with complete response (CR) or >90% reduction of tumor load, after EBVD. Patients with stable or progressive disease (SD, PD) after EBVDx3 or poor compliance to the regimen received mantle or inverted Y RT at standard dose. The median follow-up of patients currently alive was 71.5 months. 129 patients achieved a CR after EBVD and 10 a >90% reduction of tumor load, for a post-CT response rate of 94%. Eight patients had SD after EBVDx3 and one had a partial response with poor compliance. All 9 patients received mantle or inverted Y RT and 8/9 achieved a CR. Nine patients relapsed at a median of 7 months from the end of treatment. At 10 years, FFS was 90% and overall survival 95%. Six patients have died so far; 5 of HD and one of stroke. One patient developed a diffuse large cell lymphoma 48 months after the diagnosis of HD, We conclude that EBVD followed by LDIF RT is a highly effective regimen for patients with CS I-IIA HD, Longer follow up is required to assess the risk of secondary malignancies, especially solid tumors.
引用
收藏
页码:131 / 143
页数:13
相关论文
共 62 条
[1]   A RANDOMIZED STUDY OF ADJUVANT MVPP CHEMOTHERAPY AFTER MANTLE RADIOTHERAPY IN PATHOLOGICALLY STAGED IA-IIB HODGKINS-DISEASE - 10-YEAR FOLLOW-UP [J].
ANDERSON, H ;
CROWTHER, D ;
DEAKIN, DP ;
RYDER, WDJ ;
RADFORD, JA .
ANNALS OF ONCOLOGY, 1991, 2 :49-54
[2]  
ANDRIEU JM, 1980, CANCER-AM CANCER SOC, V46, P2126, DOI 10.1002/1097-0142(19801115)46:10<2126::AID-CNCR2820461003>3.0.CO
[3]  
2-F
[4]   DRUGS 10 YEARS LATER - EPIRUBICIN [J].
BONADONNA, G ;
GIANNI, L ;
SANTORO, A ;
BONFANTE, V ;
BIDOLI, P ;
CASALI, P ;
DEMICHELI, R ;
VALAGUSSA, P .
ANNALS OF ONCOLOGY, 1993, 4 (05) :359-369
[5]  
BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO
[6]  
2-7
[7]   EFFICACY AND TOXICITY OF VINBLASTINE, BLEOMYCIN, AND METHOTREXATE WITH INVOLVED-FIELD RADIOTHERAPY IN CLINICAL STAGE IA AND IIA HODGKINS-DISEASE - A BRITISH NATIONAL LYMPHOMA INVESTIGATION PILOT-STUDY [J].
BOTES, NP ;
WILLIAMS, MV ;
BESSELL, EM ;
HUDSON, GV ;
HUDSON, BV .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :288-296
[8]   IMPROVED SURVIVAL IN ADVANCED HODGKINS-DISEASE WITH THE USE OF COMBINED MODALITY THERAPY [J].
BRIZEL, DM ;
WINER, EP ;
PROSNITZ, LR ;
SCOTT, J ;
CRAWFORD, J ;
MOORE, JO ;
GOCKERMAN, JP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (03) :535-542
[9]   CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].
CANELLOS, GP ;
ANDERSON, JR ;
PROPERT, KJ ;
NISSEN, N ;
COOPER, MR ;
HENDERSON, ES ;
GREEN, MR ;
GOTTLIEB, A ;
PETERSON, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484
[10]   ETOPOSIDE, VINBLASTINE, AND DOXORUBICIN - AN ACTIVE REGIMEN FOR THE TREATMENT OF HODGKINS-DISEASE IN RELAPSE FOLLOWING MOPP [J].
CANELLOS, GP ;
PETRONI, GR ;
BARCOS, M ;
DUGGAN, DB ;
PETERSON, BA .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2005-2011